Oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) will be reporting results this Tuesday after market close. Here’s what investors should know.
NeoGenomics beat analysts’ revenue expectations last quarter, reporting revenues of $190.2 million, up 10.6% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Is NeoGenomics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting NeoGenomics’s revenue to grow 9.8% year on year, improving from the 7.5% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. NeoGenomics has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at NeoGenomics’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Quest delivered year-on-year revenue growth of 9.2%, beating analysts’ expectations by 2.7%, and Elevance Health reported revenues up 1.5%, topping estimates by 2.4%. Quest traded up 3.9% following the results while Elevance Health was also up 5.5%.
Read our full analysis of Quest’s results here and Elevance Health’s results here.
There has been positive sentiment among investors in the healthcare providers & services segment, with share prices up 10.1% on average over the last month. NeoGenomics is up 13.7% during the same time and is heading into earnings with an average analyst price target of $14.19 (compared to the current share price of $8.32).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
